细胞外基质重塑生物标志物与晚期慢性肝病严重程度及结局相关
本研究纳入232例稳定期晚期慢性肝病(ACLD)患者,检测细胞外基质(ECM)重塑生物标志物及ELF评分,分析其与疾病严重程度和肝脏相关事件(LRE)的关系。结果显示ECM重塑标志物在失代偿期ACLD和门脉高压严重患者中升高,纤维生成标志物可预测代偿期ACLD首次失代偿,而PRO-C4、C3M对LRE有独立预后价值。
要点
- ECM重塑标志物在失代偿期ACLD和门脉高压严重患者中升高。
- 纤维生成标志物(ELF、PRO-C3/-C4/-C6)可预测代偿期ACLD首次失代偿。
- PRO-C4、C3M对ACLD患者肝脏相关事件有独立预后价值。
核心结论
- ECM重塑生物标志物反映ACLD门脉高压和疾病严重程度,其预后价值主要限于代偿期ACLD。
研究设计与样本
- 纳入232例稳定期ACLD患者,测量HVPG及ECM重塑生物标志物和ELF评分,中位随访28.9个月。
- 在独立代偿期ACLD队列(n=185)中验证纤维生成标志物的预测价值。
主要发现
- 失代偿期ACLD患者ECM重塑标志物升高,且随HVPG严重程度增加(除PRO-C18L外,均p<0.05)。
- 胶原降解标志物C3M和C4M随HVPG升高(p<0.01),C6Ma3无此变化。
- 纤维生成标志物(ELF、PRO-C3/-C4/-C6)预测代偿期ACLD首次失代偿,失代偿期ACLD中无临床意义关联。
- 多变量Cox回归中,PRO-C4(aHR每100 ng/mL:1.22,p<0.001)和C3M(aHR每ng/mL:0.98,p=0.044)对LRE有独立预后价值。
关键数值与推荐
- HVPG分组:6-9 mmHg(n=28)、10-19 mmHg(n=124)、≥20 mmHg(n=80)。
- LRE定义:失代偿、慢加急性肝衰竭或肝病相关死亡。
- 中位HVPG 18(13-21)mmHg,中位MELD 11(9-14)。
临床怎么用
- ECM重塑生物标志物可用于评估ACLD疾病严重程度和门脉高压。
- 纤维生成标志物有助于代偿期ACLD首次失代偿的风险分层。
- PRO-C4和C3M可能作为ACLD患者LRE的预后指标。
局限性
- 预后价值主要限于代偿期ACLD,失代偿期ACLD中关联有限。
- 未来需研究重复测量是否改善风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Extracellular matrix (ECM) remodelling in advanced chronic liver disease (ACLD) is characterised by hepatic fibrosis and (sinusoidal) basement membrane development contributing to portal hypertension (PH) and clinical complications. METHODS: Patients with stable ACLD (n = 232) undergoing hepatic venous pressure gradient (HVPG) measurement were included. Blood biomarkers reflecting fibrosis formation (PRO-C3, PRO-C6, PRO-C4 and PRO-C18L) and degradation (C3M, C4M and C6Ma3), as well as the Enhanced Liver Fibrosis (ELF) score were measured. Associations with disease severity and liver-related events (LRE: decompensation, acute-on-chronic liver failure, or liver-related death) were analysed. RESULTS: The cohort included 131 (57%) patients with decompensated ACLD (dACLD), median HVPG 18 (13-21) mmHg and MELD 11 (9-14). ECM remodelling biomarkers increased in patients with dACLD and with PH severity (HVPG 6-9: n = 28, 10-19: n = 124, ≥ 20 mmHg: n = 80; all p < 0.05), except PRO-C18L (p = 0.231). Collagen degradation markers C3M and C4M-but not C6Ma3-also increased with HVPG (p < 0.01). Median follow-up was 28.9 (IQR 12.0-43.6) months. Fibrogenesis biomarkers (ELF, PRO-C3/-C4/-C6) were predictive of first decompensation in cACLD, while no clinically meaningful association with LRE was observed in dACLD. In multivariate Cox regression models adjusted for HVPG, MELD, albumin, and decompensation state, PRO-C4 (aHR per 100 ng/mL: 1.22, p < 0.001), C3M (aHR per ng/mL: 0.98, p = 0.044), and C4M (aHR per ng/mL: 0.98, p = 0.084) displayed independent prognostic value for LRE. The predictive value of fibrogenesis biomarkers for first decompensation (ELF, PRO-C3, PRO-C6) was validated in an independent cACLD cohort (n = 185). CONCLUSION: ECM remodelling biomarkers reflect PH and disease severity in ACLD. Their prognostic value for disease progression is largely restricted to cACLD. Future studies should investigate whether repeated measurements improve risk stratification. TRIAL REGISTRATION: NCT03267615.
引用
- Simbrunner B, Villesen IF, Semmler G, et al. Biomarkers of Extracellular Matrix Remodelling Are Linked to Severity and Outcome of Advanced Chronic Liver Disease. Aliment Pharmacol Ther. 2025. PMID: 41077886. doi:10.1111/apt.70407
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。